Literature DB >> 28454254

Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature.

Yun Liang1, Luyin Ding1, Xian Li1, Weiqin Wang1, Xiaohong Zhang1.   

Abstract

Adult sporadic Burkitt lymphoma (BL) is a rare aggressive neoplasm and represents ~1-5% of all lymphomas diagnosed in adults. The disease exhibits an aggressive clinical manifestation, which frequently involves the central nervous system (CNS) in the early stages, and is usually accompanied by abnormalities in cerebrospinal fluid (CSF) examinations and/or neuroradiography. The current study describes the rare case of a 29-year-old man who presented with oculomotor nerve palsy without palpated masses, B symptoms, peripheral blood anomaly and abnormalities of the nervous system. The patient was initially misdiagnosed with abducens diplopia, but was subsequently confirmed to have BL with early CNS invasion. Epstein-Barr virus and human immunodeficiency virus infection were negative. Intensive systemic chemotherapy with hyperfractionated cyclophosphamide, vincristine, therarubicin and dexamethasone (hyper-CVAD, cyclophosphamide 600 mg/m2 on days 2-4; vincristine 1.4 mg/m2 on days 5 and 12, therarubicin 50 mg/m2 on day 5 and dexamethasone 40 mg on days 2-5 and 12-15), including intrathecal chemotherapy with methotrexate (5 mg), arabinocytidine (5 mg) and dexamethasone (5 mg), was determined as an appropriate treatment. Rituximab (375 mg/m2 on day 1) was administered alongside chemotherapy to increase treatment efficacy. The patient temporarily underwent complete remission, but subsequently relapsed as no suitable bone marrow donor was available. Adult sporadic BL with early CNS invasion, which traditional tests such as neuroradiography and CSF examination fail to identify, is uncommon. Therefore, appropriate diagnostic tests are critical for accurate diagnosis and must be performed immediately, particularly in patients that present with unusual image and laboratory manifestations.

Entities:  

Keywords:  Burkitt lymphoma; oculomotor nerve palsy; rituximab

Year:  2017        PMID: 28454254      PMCID: PMC5403323          DOI: 10.3892/ol.2017.5583

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

Review 1.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

Review 2.  Burkitt lymphoma--a stalking horse for cancer research?

Authors:  George Klein
Journal:  Semin Cancer Biol       Date:  2009-07-14       Impact factor: 15.707

Review 3.  Molecular biology of Burkitt's lymphoma.

Authors:  J L Hecht; J C Aster
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

4.  Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.

Authors:  Giuseppe Todeschini; Massimiliano Bonifacio; Cristina Tecchio; Rita Balter; Giuseppe Carli; Piero Maria Stefani; Fausto Adami; Alberto Zamò; Angelo Paolo Dei Tos; Filippo Marino; Filippo Gherlinzoni; Pierluigi Marradi; Giampietro Semenzato; Giovanni Pizzolo
Journal:  Am J Hematol       Date:  2011-11-16       Impact factor: 10.047

5.  Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

Authors:  Mitchell S Cairo; Mary Gerrard; Richard Sposto; Anne Auperin; C Ross Pinkerton; Jean Michon; Claire Weston; Sherrie L Perkins; Martine Raphael; Keith McCarthy; Catherine Patte
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.

Authors:  Estrella Carrillo-Cruz; Víctor A Marín-Oyaga; María Solé Rodríguez; Isabel Borrego-Dorado; Fátima de la Cruz Vicente; Eduardo Quiroga Cantero; Marina Manzanares Pérez; Francisco J Capote; María J Ramírez Sánchez; Ildefonso Espigado Tocino; Herminia Pérez-Vega; Ricardo Vázquez-Albertino; Jose A Pérez-Simón
Journal:  Eur J Haematol       Date:  2015-01       Impact factor: 2.997

7.  The imaging of Burkitt's and Burkitt-like lymphoma.

Authors:  K A Johnson; K Tung; G Mead; J Sweetenham
Journal:  Clin Radiol       Date:  1998-11       Impact factor: 2.350

8.  Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens.

Authors:  S Smeland; A K Blystad; S O Kvaløy; I M Ikonomou; J Delabie; G Kvalheim; J Hammerstrøm; G F Lauritzsen; H Holte
Journal:  Ann Oncol       Date:  2004-07       Impact factor: 32.976

9.  A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Authors:  Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

10.  CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.

Authors:  J E C Bromberg; D A Breems; J Kraan; G Bikker; B van der Holt; P Sillevis Smitt; M J van den Bent; M van't Veer; J W Gratama
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

View more
  2 in total

1.  Sixth nerve palsy in sporadic Burkitt Lymphoma.

Authors:  Sowmya Yennam; Ashwini T Kini; Bayan Al Othman; Andrew G Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2019-10-31

Review 2.  Rare central nervous system lymphomas.

Authors:  Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox
Journal:  Br J Haematol       Date:  2022-03-16       Impact factor: 8.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.